APVO — Aptevo Therapeutics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1671584 ·
Last close
$0.46
Market Cap
$834.5K
52W High
$25.56
52W Low
$0.45
ADV30
81,835
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -6,443,000 -6,356,000 14,519,000 9,797,000 8,478,000
Mar 2026 0 — -6,837,000 -6,697,000 19,902,000 14,524,000 8,290,000
Dec 2025 0 — -5,996,000 -5,806,000 27,194,000 21,619,000 9,813,000
Sep 2025 0 — -7,610,000 -7,549,000 26,996,000 21,061,000 9,604,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-25,343,000
Investing CF
$0
Financing CF
$25,730,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-203.15
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-288,264,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-26,886,000
Pretax Income TTM
$-26,408,000
Interest Exp TTM
—
Analysts
2

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -26,312,000 -25,967,000 27,194,000 9,813,000 17,381,000 -25,592,000
Dec 2024 0 -24,602,000 -24,130,000 15,591,000 10,836,000 4,755,000 -23,785,000
Dec 2023 0 -28,878,000 -17,411,000 24,842,000 12,621,000 12,221,000 -11,730,000
Dec 2022 3,114,000 -28,641,000 8,027,000 34,215,000 16,241,000 17,974,000 -21,022,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$-53,585,000
NetIncome TTM
$-28,076,000
OpCashFlow TTM
—
Assets (Latest)
$14,519,000
Forward EPS
$-10.40

Peers — same industry

TickerNameMarket CapLastDaily %
PTIX Protagenic Therapeutics, Inc.\new $814.6K $0.45 —
ATXI AVENUE THERAPEUTICS, INC. $922.6K $0.28 —
OGEN ORAGENICS INC $947.5K $0.21 —
SKVI SKINVISIBLE, INC. $972.7K $0.18 —
GOVX GeoVax Labs, Inc. $1.09M $2.01 —

News headlines (Yahoo Finance, 1h cache)

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
2026-11-16 13:30 · Yahoo
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross Proceeds
2026-11-12 21:15 · Yahoo
Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds
2026-11-11 14:00 · Yahoo
Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors
2026-11-09 13:30 · Yahoo
Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
2026-11-05 13:30 · Yahoo
APVO: Mipletamig Combination Therapy Leads to 21% Stem Cell Transplantation Rate
2026-10-27 10:33 · Yahoo
Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
2026-10-26 12:05 · Yahoo
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
2026-10-14 12:46 · Yahoo
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
2026-09-24 12:05 · Yahoo
Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML
2026-09-03 14:19 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.